Celiac disease: From oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesis

Mucosal Immunology

Volumn 2, Issue 1, 2009, Pages 8-23

  Meresse, B ^a   Ripoche, J ^a   Heyman, M ^a   Cerf Bensussan, N ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; NATURAL KILLER CELL RECEPTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELIAC DISEASE; CYTOKINE RELEASE; ENTERITIS; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; LAMINA PROPRIA; LYMPHOCYTE ACTIVATION; LYMPHOMA; MUCOSAL IMMUNITY; NONHUMAN; NUTRITIONAL TOLERANCE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 58149119708     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2008.75     Document Type: Review

References (160)

1. Van de Kamer, J., Weijers, H. & Dicke, W. Coeliac disease V. Some experiments on the cause of the harmful effect of wheat gliadin. Acta Paediatr. Scand. 42, 223-231 (1953).
2. Sakula, J. & Shiner, M. Coeliac disease with atrophy of the small-intestine mucosa. Lancet 273, 876-877 (1957).
3. Ferguson, A. & Murray, D. Quantitation of intraepithelial lymphocytes in human jejunum. Gut 12, 988-994 (1971).
4. Carter, C., Sheldon, W. & Walker, C. The inheritance of coeliac disease. Ann. Hum. Genet. 23, 266-278 (1959).
5. Greco, L. et al. The first large population based twin study of coeliac disease. Gut 50, 624-628 (2002).
6. Dieterich, W. et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3, 797-801 (1997).
7. Howell, M.D., Austin, R.K., Kelleher, D., Nepom, G.T. & Kagnoff, M.F. An HLA-D region restriction fragment length polymorphism associated with celiac disease. J. Exp. Med. 164, 333-338 (1986).
8. Sollid, L.M., Markussen, G., Ek, J., Gjerde, H., Vardtal, F. & Thorsby, E. Evidence for a primary association of celiac disease to a particular HLA-DQ a/b heterodimer. J. Exp. Med. 169, 345-350 (1989).
9. Sollid, L.M. Molecular basis of celiac disease. Annu. Rev. Immunol. 18, 53-81 (2000).
10. Cosnes, J. et al. Incidence of autoimmune diseases in celiac disease: Protective effect of the gluten-free diet. Clin. Gastroenterol. Hepatol. 6, 753-758 (2008).
11. Cellier, C. et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group [see comments]. Lancet 356, 203-208 (2000).
12. Cellier, C. et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 114, 471-481 (1998).
13. Spencer, J. et al. Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes. Am. J. Pathol. 132, 1-5 (1988).
14. Sollid, L. Coeliac disease: Dissecting a complex inflammatory disorder. Nat. Rev. Immunol. 9, 647-655 (2002).
15. Kagnoff, M.F. Celiac disease: Pathogenesis of a model immunogenetic disease. J. Clin. Invest. 117, 41-49 (2007).
16. Lundin, K.E.A. et al. Gliadin-specific, HLA-DQ(a1*0501,b1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J. Exp. Med. 178, 187-196 (1993).
17. Van de Wal, Y. et al. Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc. Natl. Acad. Sci. USA 95, 10050-10054 (1998).
18. Bethune, M.T. & Khosla, C. Parallels between pathogens and gluten peptides in celiac sprue. PLoS Pathog. 4, e34 (2008).
19. Wieser, H. Chemistry of gluten proteins. Food Microbiol. 24, 115-119 (2007).
20. Frazer, A. et al. Gluten-induced enteropathy: The effect of partially digested gluten. Lancet 2, 252-255 (1959).
21. Shan, L. et al. Structural basis for gluten intolerance in celiac sprue. Science 297, 2218-2220 (2002).
22. Qiao, S.W. et al. Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion. J. Immunol. 173, 1757-1762 (2004).
23. Siegel, M. et al. Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS ONE 3, e1861 (2008).
24. Fesus, L. & Piacentini, M. Transglutaminase 2: An enigmatic enzyme with diverse functions. Trends Biochem. Sci. 27, 534-539 (2002).
25. Sollid, L.M., Molberg, O., McAdam, S. & Lundin, K.E. Autoantibodies in coeliac disease: Tissue transglutaminase - guilt by association? Gut 41, 851-852 (1997).
26. Vader, L. et al. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J. Exp. Med. 195, 643-649 (2002).
27. Molberg, O. et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4, 713-717 (1998).
28. Van de Wal, Y. et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specfic T cell reactivity. J. Immunol. 161, 1585-1588 (1998).
29. Kim, C.Y., Quarsten, H., Bergseng, E., Khosla, C. & Sollid, L.M. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc. Natl. Acad. Sci. USA 101, 4175-4179 (2004).
30. Qiao, S.W. et al. Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: importance of proline spacing and glutamine deamidation. J. Immunol. 175, 254-261 (2005).
31. Stepniak, D. et al. Large-scale characterization of natural ligands explains the unique gluten-binding properties of HLA-DQ2. J. Immunol. 180, 3268-3278 (2008).
32. Vader, L.W. et al. Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology 125, 1105-1113 (2003).
33. Raki, M. et al. A unique dendritic cell subset accumulates in the celiac lesion and effi ciently activates gluten-reactive T cells. Gastroenterology 131, 428-438 (2006).
34. Nilsen, E., Lundin, K., Krajci, P., Sollid, L. & Brantzaeg, P. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with TH1 or TH0 profile dominated by interferon g. Gut 37, 766-776 (1995).
35. Guy-Grand, D., Disanto, J.P., Henchoz, P., Malassis-Seris, M. & Vassalli, P. Small bowel enteropathy - role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-γ, TNF) in the induction of epithelial cell death and renewal. Eur. J. Immunol. 28, 730-744 (1998).
36. Vader, W. et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc. Natl. Acad. Sci. USA 100, 12390-12395 (2003).
37. Al-Toma, A. et al. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin. Gastroenterol. Hepatol. 3, 315-319 (2006).
38. Malamut, G. et al. Presentation and long-term follow-up of refractory celiac disease: Comparison of type I and type II. Gastroenterology (in press).
39. Matysiak-Budnik, T. et al. Long-term follow-up of 61 coeliac patients diagnosed in childhood: Evolution toward latency is possible on a normal diet. Gut 56, 1379-1386 (2007).
40. Mäki, M., Holm, K., Collin, P. & Savilahti, E. Increase in γ/δ T cell receptor bearing lymphocytes in normal small bowel mucosa in latent celiac disease. Gut 32, 1412-1414 (1991).
41. Weiner, H. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev. 182 207-214 (2001).
42. Black, K., Murray, J. & David, C.S. HLA-DQ determines the response to exogenous wheat proteins: A model of gluten sensitivity in transgenic knockout mice. J. Immunol. 169, 5595-5600 (2002).
43. Marietta, E. et al. A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J. Clin. Invest. 114, 1090-1097 (2004).
44. Sardy, M., Karpati, S., Merkl, B., Paulsson, M. & Smyth, N. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J. Exp. Med. 195, 747-757 (2002).
45. + (TCRαβ or TCRγδ) and CD3-lymphocytes isolated from normal human gut epithelium differ from their PBL counterparts. Eur. J. Immunol. 20, 1097-1103 (1990).
46. + intraepithelial lymphocytes correlate with the grade of villous atrophy in coeliac patients on a long term normal diet. Gut 34, 208-214 (1993).
47. Ciccocioppo, R. et al. Increased enterocyte apoptosis and Fas-Fas ligand system in celiac disease. Am. J. Clin. Pathol. 115, 494-503 (2001).
48. Di Sabatino, A. et al. Intraepithelial and lamina propria lymphocytes show distinct patterns of apoptosis whereas both populations are active in Fas based cytotoxicity in coeliac disease. Gut 49 380-386 (2001).
49. Oberhuber, G. et al. Evidence that intestinal intraepithelial lymphocytes are activated cytotoxic T cells in celiac disease but not in Giardiasis. Am. J. Pathol. 148, 1351-1357 (1996).
50. Olaussen, R.W. et al. Interferon-gamma-secreting T cells localize to the epithelium in coeliac disease. Scand. J. Immunol. 56, 652-664 (2002).
51. Bhagat, G. et al. Small intestinal CD8TCRgammadeltaNKG2A intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. J. Clin. Invest. 118, 281-293 (2008).
52. Verkarre, V. et al. Recurrent partial trisomy 1q22-q42 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology 125, 40-46 (2003).
53. Badgi, E., Diss, T., Munson, P. & Isaacson, P. Mucosal intraepithelial lymphocytes in enteropathy-associated T-cell lymphoma, unlcerative jejunitis, and refractory celiac sprue constitute a neoplastic population. Blood 94, 260-264 (1999).
54. Daum, S., Cellier, C. & Mulder, C.J. Refractory coeliac disease. Best Pract. Res. Clin. Gastroenterol. 19, 413-424 (2005).
55. Al-Toma, A., Verbeek, W.H., Hadithi, M., von Blomberg, B.M. & Mulder, C.J. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: Retrospective evaluation of single-centre experience. Gut 56, 1373-1378 (2007).
56. Gianfrani, C. et al. Celiac disease association with CD8(+) T cell responses: Identification of a novel gliadin-derived HLA-A2-restricted epitope. J. Immunol. 170, 2719-2726 (2003).
57. + T cells in celiac disease intestinal mucosa and induces the enterocyte apoptosis. Gastroenterology 134, 1017-1027 (2008).
58. Hue, S. et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21, 367-377 (2004).
59. Jabri, B. et al. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 118, 867-879 (2000).
60. Meresse, B. et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21, 357-366 (2004).
61. Di Sabatino, A. et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 55, 469-477 (2006).
62. Mention, J.J. et al. Interleukin 15: A key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 125, 730-745 (2003).
63. Budagian, V., Bulanova, E., Paus, R. & Bulfone-Paus, S. IL-15/IL-15 receptor biology: A guided tour through an expanding universe. Cytokine Growth Factor Rev. 17, 259-280 (2006).
64. Fehniger, T.A. & Caligiuri, M.A. Interleukin 15: Biology and relevance to human disease. Blood 97, 14-32 (2001).
65. Bergamaschi, C. et al. Intracellular interaction of IL-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J. Biol. Chem. 283, 4189-4199 (2008).
66. + T cells. J. Exp. Med. 193, 219-231 (2001).
67. Ben Ahmed, M. et al. Inhibition of TGF-beta signaling by interleukin-15 via phospho-c-jun upregulation: A new role for interleukin-15 in the loss of immune homeostasis in celiac disease. Gastroenterology 132, 994-1008 (2007).
68. Fina, D. et al. Interleukin-21 contributes to the mucosal T helper cell type 1 response in celiac disease. Gut (2007).
69. Maiuri, L. et al. Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 119, 996-1006 (2000).
70. + T cells. Proc. Natl. Acad. Sci. USA 101, 15154-15159 (2004).
71. Roberts, A.I. et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J. Immunol. 167, 5527-5530 (2001).
72. Raulet, D. Roles of NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3, 781-790 (2003).
73. Groh, V., Steinle, A., Bauer, S. & Spies, T. Recognition of stress-induced MHC molecules by intestinal gammadelta T cells. Science 279, 1737-1740 (1998).
74. Jabri, B. & Meresse, B. NKG2 receptor-mediated regulation of effector CTL functions in the human tissue microenvironment. Curr. Top Microbiol. Immunol. 298, 139-156 (2006).
75. Jabri, B. et al. TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity 17, 487-499 (2002).
76. + deficient mice display abnormal but distinct phenotypes toward a natural, widespread infection of the intestinal epithelium. Proc. Natl. Acad. Sci. USA 93, 11774-11779 (1996).
77. Meresse, B. et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J. Exp. Med. 203, 1343-1355 (2006).
78. Terrazzano, G. et al. Gliadin regulates the NK-dendritic cell cross-talk by HLA-E surface stabilization. J. Immunol. 179, 372-381 (2007).
79. Lieto, L.D., Borrego, F., You, C.H. & Coligan, J.E. Human CD94 gene expression: Dual promoters differing in responsiveness to IL-2 or IL-15. J. Immunol. 171, 5277-5286 (2003).
80. Laouar, A. et al. Cutting edge: Distinct NK receptor profiles are imprinted on CD8 T cells in the mucosa and periphery during the same antigen challenge: Role of tissue-specific factors. J. Immunol. 178, 652-656 (2007).
81. Mora, J., Iwata, M. & von Andrian, U. Vitamin effects on the immune system: Vitamins A and D take centre stage. Nat. Rev. Immunol. (2008)) [Epub ahead of print].
82. Gunturi, A., Berg, R. E., Crossley, E., Murray, S. & Forman, J. The role of TCR stimulation and TGF-beta in controlling the expression of CD94/NKG2A receptors on CD8 T cells. Eur. J. Immunol. 35, 766-775 (2005).
83. Rubtsov, Y.P. & Rudensky, A.Y. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat. Rev. Immunol. 7, 443-453 (2007).
84. Yang, X. et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 18, 1280-1291 (1999).
85. Castriconi, R. et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100, 4120-4125 (2003).
86. Marie, J.C., Liggitt, D. & Rudensky, A.Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 25, 441-454 (2006).
87. Zhou, R., Wei, H., Sun, R., Zhang, J. & Tian, Z. NKG2D recognition mediates Toll-like receptor 3 signaling-induced breakdown of epithelial homeostasis in the small intestines of mice. Proc. Natl. Acad. Sci. USA 104, 7512-7515 (2007).
88. Falchuk, Z.M., Gebhard, R.L., Sessoms, C. & Strober, W. An in vitro model of gluten-sensitive enteropathy. Effect of gliadin on intestinal epithelial cells of patients with gluten-sensitive enteropathy in organ culture. J. Clin. Invest. 53, 487-500 (1974).
89. Falchuk, Z.M. et al. Gluten-sensitive enteropathy. Influence of histocompatibility type on gluten sensitivity in vitro. J. Clin. Invest. 66, 227-233 (1980).
90. Maiuri, L. et al. FAS engagement drives apoptosis of enterocytes of coeliac patients. Gut 48, 418-424 (2001).
91. de Ritis, G. et al. In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in celiac disease. Gastroenterology 94, 41-49 (1988).
92. Sturgess, R. et al. Wheat peptide challenge in coeliac disease. Lancet 343, 758-761 (1994).
93. Maiuri, L. et al. In vitro activities of A-gliadin-related synthetic peptides: Damaging effect on the atrophic coeliac mucosa and activation of mucosal immune response in the treated coeliac mucosa. Scand. J. Gastroenterol. 31, 247-253 (1996).
94. Maiuri, L. et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 362, 30-37 (2003).
95. Maiuri, L. et al. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 129, 1400-1413 (2005).
96. Barone, M.V. et al. Growth factor-like activity of gliadin, an alimentary protein: Implications for celiac disease. Gut 56, 480-488 (2007).
97. Cinova, J. et al. Gliadin peptides activate blood monocytes from patients with celiac disease. J. Clin. Immunol. 27, 201-209 (2007).
98. De Stefano, D. et al. The role of NF-kappaB, IRF-1, and STAT-1alpha transcription factors in the iNOS gene induction by gliadin and IFN-gamma in RAW 264.7 macrophages. J. Mol. Med. 84, 65-74 (2006).
99. Palova-Jelinkova, L. et al. Gliadin fragments induce phenotypic and functional maturation of human dendritic cells. J. Immunol. 175, 7038-7045 (2005).
100. Thomas, K.E., Sapone, A., Fasano, A. & Vogel, S.N. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: Role of the innate immune response in Celiac disease. J. Immunol. 176, 2512-2521 (2006).
101. Tuckova, L. et al. Activation of macrophages by gliadin fragments: isolation and characterization of active peptide. J. Leukoc. Biol. 71, 625-631 (2002).
102. Halttunen, T. & Maki, M. Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. Gastroenterology 116, 566-572 (1999).
103. Myrsky, E. et al. Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis. Clin. Exp. Immunol. 152, 111-119 (2008).
104. Zanoni, G. et al. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med. 3, e358 (2006).
105. Kaukinen, K. et al. Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: A prospective and randomized clinical study. Scand. J. Gastroenterol. 40, 564-572 (2005).
106. Tosco, A. et al. Immunoglobulin A anti-tissue transglutaminase antibody deposits in the small intestinal mucosa of children with no villous atrophy. J. Pediatr. Gastroenterol. Nutr. 47, 293-298 (2008).
107. Esposito, C. et al. Anti-tissue transglutaminase antibodies from coeliac patients inhibit transglutaminase activity both in vitro and in situ. Gut 51, 177-181 (2002).
108. Preisz, K., Sardy, M., Horvath, A. & Karpati, S. Immunoglobulin, complement and epidermal transglutaminase deposition in the cutaneous vessels in dermatitis herpetiformis. J. Eur. Acad. Dermatol. Venereol. 19, 74-79 (2005).
109. Fasano, A. et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 355, 1518-1519 (2000).
110. Lammers, K.M. et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 135, 194-204 e3 (2008).
111. Monsuur, A.J. et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat. Genet. 37, 1341-1344 (2005).
112. Matysiak-Budnik, T. et al. Alterations of the intestinal transport and processing of gliadin peptides in celiac disease. Gastroenterology 125, 696-707 (2003).
113. Matysiak-Budnik, T. et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J. Exp. Med. 205, 143-154 (2008).
114. Schumann, M. et al. Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut 57, 747-754 (2008).
115. Yang, P., Berin, M.C., Yu, L., Conrad, D. & Perdue, M. Enhanced intestinal transepithelial antigen transport in allergic rats is mediated by IgE and CD23 (FcepsilonRII). J. Clin. Invest 106 879-886 (2000).
116. Yoshida, M. et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20, 769-783 (2004).
117. Yamashiro, D.J., Tycko, B., Fluss, S.R. & Maxfield, F.R. Segregation of transferrin to a mildly acidic (pH 6.5) para-Golgi compartment in the recycling pathway. Cell 37, 789-800 (1984).
118. Moura, I. C. et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J. Exp. Med. 194, 417-425 (2001).
119. Barisani, D. et al. Adaptive changes of duodenal iron transport proteins in celiac disease. Physiol. Genomics 17, 316-325 (2004).
120. Qiao, S. W. et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc. Natl. Acad. Sci. USA 105, 9337-9342 (2008).
121. Mazzarella, G. et al. Constitutive activation of the signal transducer and activator of transcription pathway in celiac disease lesions. Am. J. Pathol. 162, 1845-1855 (2003).
122. Biron, C.A. Interferons α and β as immune regulators-a new look. Immunity 14, 661-664 (2001).
123. Monteleone, G. et al. Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut 48, 425-429 (2001).
124. Stepniak, D. & Koning, F. Celiac disease - sandwiched between innate and adaptive immunity. Hum. Immunol. 67, 460-468 (2006).
125. Monteleone, G., Pender, S.L.F., Wathen, N.C. & MacDonald, T.T. Interferon-a drives T-cell mediated immunopathology in the intestine. Eur. J. Immunol. 31, 2247-2255 (2001).
126. Di Sabatino, A. et al. Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology 133, 1175-1187 (2007).
127. Salvati, V.M. et al. Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut 50, 186-190 (2002).
128. Gary-Gouy, H., Lebon, P. & Dalloul, A.H. Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. J. Interferon Cytokine Res. 22, 653-659 (2002).
129. Mattei, F., Schiavoni, G., Belardelli, F. & Tough, D. F. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J. Immunol. 167, 1179-1187 (2001).
130. + T cell response during cross-priming. J. Immunol. 176, 4682-4689 (2006).
131. Leonard, W.J. & Spolski, R. Interleukin-21: A modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5, 688-698 (2005).
132. Brandt, K., Singh, P.B., Bulfone-Paus, S. & Ruckert, R. Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev. 18, 223-232 (2007).
133. + T cells. J. Immunol. 176, 1490-1497 (2006).
134. + T cell expansion and function. J. Exp. Med. 201, 139-148 (2005).
135. Torgerson, T.R. et al. Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. Gastroenterology 132, 1705-1717 (2007).
136. Bjornvold, M. et al. FOXP3 polymorphisms in type 1 diabetes and coeliac disease. J. Autoimmun. 27, 140-144 (2006).
137. Tiittanen, M., Westerholm-Ormio, M., Verkasalo, M., Savilahti, E. & Vaarala, O. Infi Infiltration of forkhead box P3-expressing cells in small intestinal mucosa in coeliac disease but not in type 1 diabetes. Clin. Exp. Immunol. 152, 498-507 (2008).
138. + T lymphocytes. J. Immunol. 178, 732-739 (2007).
139. Abel, M. et al. Adulthood-onset celiac disease is associated with intercellular adhesion molecule-1 (ICAM-1) gene polymorphism. Hum. Immunol. 67, 612-617 (2006).
140. Dubois, P.C. & van Heel, D.A. Translational mini-review series on the immunogenetics of gut disease: Immunogenetics of coeliac disease. Clin. Exp. Immunol. 153, 162-173 (2008).
141. Djilali-Saiah, I. et al. CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut 43, 187-189 (1998).
142. Hunt, K.A. et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat. Genet. 40 395-402 (2008).
143. van Heel, D.A. et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat. Genet. 39, 827-829 (2007).
144. Adamovic, S. et al. Association study of IL2/IL21 and FcgRIIa: significant association with the IL2/IL21 region in Scandinavian coeliac disease families. Genes Immun. 9, 364-367 (2008).
145. Yamanouchi, J. et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 39, 329-337 (2007).
146. Meresse, B., Verdier, J. & Cerf-Bensussan, N. The cytokine interleukin 21: A new player in coeliac disease? Gut 57, 879-881 (2008).
147. Verkarre, V. et al. Refractory celiac sprue is a diffuse gastrointestinal disease. Gut 52, 205-211 (2003).
148. Kagnoff, M.F., Austin, R.K., Hubert, J.J., Bernardin, J.E. & Kasarda, D.D. Possible role for a human adenovirus in the pathogenesis of celiac disease. J. Exp. Med. 160, 1544-1557 (1984).
149. Nieuwenhuizen, W.F., Pieters, R.H., Knippels, L.M., Jansen, M.C. & Koppelman, S.J. Is Candida albicans a trigger in the onset of coeliac disease? Lancet 361, 2152-2154 (2003).
150. Forsberg, G. et al. Presence of bacteria and innate immunity of intestinal epithelium in childhood celiac disease. Am. J. Gastroenterol. 99, 894-904 (2004).
151. Stene, L.C. et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: A longitudinal study. Am. J. Gastroenterol. 101, 2333-2340 (2006).
152. Troncone, R., Ivarsson, A., Szajewska, H. & Mearin, M. L. Review article: Future research on coeliac disease - a position report from the European multistakeholder platform on coeliac disease (CDEUSSA). Aliment Pharmacol. Ther. 27, 1030-1043 (2008).
153. Siegel, M., Xia, J. & Khosla, C. Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg. Med. Chem. 15, 6253-6261 (2007).
154. Xia, J. et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg. Med. Chem. 15, 6565-6573 (2007).
155. Cerf-Bensussan, N., Matysiak-Budnik, T., Cellier, C. & Heyman, M. Oral proteases: A new approach to managing coeliac disease. Gut 56 157-160 (2007).
156. Gass, J., Bethune, M.T., Siegel, M., Spencer, A. & Khosla, C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 133, 472-480 (2007).
157. Stepniak, D. et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: Implications for celiac disease. Am. J. Physiol. Gastrointest. Liver Physiol. 291, G621-G629 (2006).
158. Bethune, M.T. et al. A non-human primate model for gluten sensitivity. PLoS ONE 3, e1614 (2008).
159. Bethune, M.T., Ribka, E., Khosla, C. & Sestak, K. Transepithelial transport and enzymatic detoxification of gluten in gluten-sensitive rhesus macaques. PLoS ONE 3, e1857 (2008).
160. Verkarre, V., Romana, S.P. & Cerf-Bensussan, N. Gluten-free diet, chromosomal abnormalities, and cancer risk in coeliac disease. J. Pediatr. Gastroenterol. Nutr. 38, 140-142 (2004).